New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2013
08:31 EDTXONAgilis and Intrexon announce exclusive channel collaboration
Agilis Biotherapeutics and Intrexon announced an exclusive channel collaboration to develop DNA-based therapeutics for Friedreich's ataxia, a rare genetic neurodegenerative disease. Agilis and Intrexon expect DNA-based therapeutics to provide the ability to target underlying disease mechanisms with precision using tightly-controlled gene therapies for patients with rare inherited diseases such as FRDA. Current FRDA therapies are primarily focused on supportive care and symptom relief. There are no FDA-approved treatment options to address the cause of FRDA.
News For XON From The Last 14 Days
Check below for free stories on XON the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XON

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use